ACD PHARMACEUTICALS AS: årsregnskap 2023 vs 2022
Grew 10% on revenue, returned to profit, cash halved-plus
approved 2024-06-30; registry 2024-07-29; journal 2024 681189
Summary
What changed
Comparing Årsregnskap 2023 with 2022 for ACD PHARMACEUTICALS AS. Revenue 26.85m NOK → 29.42m NOK (+9.6%). Net result -12.27m NOK → +3.65m NOK.
On the constructive side: revenue rose; operating result improved; turned profitable. Pressures included: cash fell; current ratio dropped below 1×.
Also worth watching: sharp cash drawdown; cogs moved; book investments changed. All figures are taken from the published annual accounts for ACD PHARMACEUTICALS AS.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 26.85m NOK to 29.42m NOK (+9.6% YoY). Calculated
-
↑
Operating result improved
Operating result -15.96m NOK → +4.85m NOK (op. margin -59.4% → 16.5%). Calculated
-
↑
Turned profitable
Net result flipped from a loss of 12.27m NOK to a profit of 3.65m NOK. Calculated
What deteriorated
-
↓
Cash fell
Bank deposits 1.67m NOK → 415.2k NOK (-75.2% YoY). Calculated
-
↓
Current ratio dropped below 1×
Current ratio 4.55× → 0.42× — short-term liabilities now exceed liquid/current assets on the published lines. Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (1.67m NOK → 415.2k NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
COGS moved
COGS / varekostnad 2.71m NOK → 3.03m NOK (+11.8% YoY). Calculated
-
·
Book investments changed
Investment / intangible book value 376 NOK → 24.5k NOK. Reported fact
-
·
Headcount (årsverk) changed
Reported FTEs 5 → 7.5. Reported fact